246 reports of this reaction
2.1% of all OZANIMOD HYDROCHLORIDE reports
#9 most reported adverse reaction
COLITIS ULCERATIVE is the #9 most commonly reported adverse reaction for OZANIMOD HYDROCHLORIDE, manufactured by Celgene Corporation. There are 246 FDA adverse event reports linking OZANIMOD HYDROCHLORIDE to COLITIS ULCERATIVE. This represents approximately 2.1% of all 11,558 adverse event reports for this drug.
Patients taking OZANIMOD HYDROCHLORIDE who experience colitis ulcerative should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLITIS ULCERATIVE is a less commonly reported adverse event for OZANIMOD HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to colitis ulcerative, the following adverse reactions have been reported for OZANIMOD HYDROCHLORIDE:
The following drugs have also been linked to colitis ulcerative in FDA adverse event reports:
COLITIS ULCERATIVE has been reported as an adverse event in 246 FDA reports for OZANIMOD HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLITIS ULCERATIVE accounts for approximately 2.1% of all adverse event reports for OZANIMOD HYDROCHLORIDE, making it a notable side effect.
If you experience colitis ulcerative while taking OZANIMOD HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.